Literature DB >> 19259548

Bruton's tyrosine kinase as a drug discovery target.

Zhengying Pan1.   

Abstract

Bruton's tyrosine kinase (Btk) is an important mediator in multiple signal transduction pathways. Fifteen years of research have revealed a complex role for Btk in hematopoietic cells. These studies suggest that Btk may be a promising target for therapeutic intervention for several complicated diseases. Inhibitors targeting the Btk kinase domain have been developed and show clear beneficial effects in animal models of rheumatoid arthritis, lymphoma and other diseases. Here, an overview of these studies is presented with an emphasis on results stemming from medicinal chemistry research. Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19259548     DOI: 10.1358/dnp.2008.21.7.1255308

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  7 in total

1.  A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.

Authors:  Patrick F Smith; Janakan Krishnarajah; Philip A Nunn; Ron J Hill; Dane Karr; D Tam; Mohammad Masjedizadeh; Jens O Funk; Steve G Gourlay
Journal:  Br J Clin Pharmacol       Date:  2017-08-01       Impact factor: 4.335

2.  Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.

Authors:  Andreas Kuglstatter; April Wong; Stan Tsing; Simon W Lee; Yan Lou; Armando G Villaseñor; J Michael Bradshaw; David Shaw; Jim W Barnett; Michelle F Browner
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

3.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Authors:  Julie A Di Paolo; Tao Huang; Mercedesz Balazs; James Barbosa; Kai H Barck; Brandon J Bravo; Richard A D Carano; James Darrow; Douglas R Davies; Laura E DeForge; Lauri Diehl; Ronald Ferrando; Steven L Gallion; Anthony M Giannetti; Peter Gribling; Vincent Hurez; Sarah G Hymowitz; Randall Jones; Jeffrey E Kropf; Wyne P Lee; Patricia M Maciejewski; Scott A Mitchell; Hong Rong; Bart L Staker; J Andrew Whitney; Sherry Yeh; Wendy B Young; Christine Yu; Juan Zhang; Karin Reif; Kevin S Currie
Journal:  Nat Chem Biol       Date:  2010-11-28       Impact factor: 15.040

4.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

5.  Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer.

Authors:  Liron Bar-Peled; Esther K Kemper; Radu M Suciu; Ekaterina V Vinogradova; Keriann M Backus; Benjamin D Horning; Thomas A Paul; Taka-Aki Ichu; Robert U Svensson; Jose Olucha; Max W Chang; Bernard P Kok; Zhou Zhu; Nathan T Ihle; Melissa M Dix; Ping Jiang; Matthew M Hayward; Enrique Saez; Reuben J Shaw; Benjamin F Cravatt
Journal:  Cell       Date:  2017-09-28       Impact factor: 41.582

6.  Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release.

Authors:  Delphine Lamoral-Theys; Nathalie Wauthoz; Petra Heffeter; Véronique Mathieu; Utte Jungwirth; Florence Lefranc; Jean Nève; Jacques Dubois; François Dufrasne; Karim Amighi; Walter Berger; Philippe Gailly; Robert Kiss
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

7.  Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations.

Authors:  Angus T Voice; Gary Tresadern; Rebecca M Twidale; Herman van Vlijmen; Adrian J Mulholland
Journal:  Chem Sci       Date:  2021-01-28       Impact factor: 9.825

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.